Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Cyclin D1: polymorphism, aberrant splicing and cancer risk

Abstract

The cyclin D1 proto-oncogene exercises powerful control over the mechanisms that regulate the mitotic cell cycle, and excessive cyclin D1 expression and/or activity is common in human cancers. Although somatic mutations of the cyclin D1 locus are rarely observed, mounting evidence demonstrates that a specific polymorphism of cyclin D1 (G/A870) and a protein product of a potentially related alternate splicing event (cyclin D1b) may influence cancer risk and outcome. Herein, we review the epidemiological and functional literatures that link these alterations of cyclin D1 to human tumor development and progression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Agami R, Bernards R . (2000). Cell 102: 55–66.

  • Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A et al. (1995). J Biol Chem 270: 23589–23597.

  • Alt JR, Cleveland JL, Hannink M, Diehl JA . (2000). Genes Dev 14: 3102–3114.

  • Bala S, Peltomaki P . (2001). Cancer Res 61: 6042–6045.

  • Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J . (1994). Int J Cancer 57: 353–361.

  • Bergsagel PL, Kuehl WM . (2005). J Clin Oncol 23: 6333–6338.

  • Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J . (1995). Oncogene 11: 1005–1011.

  • Bienvenu F, Gascan H, Coqueret O . (2001). J Biol Chem 276: 16840–16847.

  • Bigoni R, Negrini M, Veronese ML, Cuneo A, Castoldi GL, Croce CM . (1996). Oncogene 13: 797–802.

  • Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N et al. (1994). Blood 84: 2726–2732.

  • Buch S, Zhu B, Davis AG, Odom D, Siegfried JM, Grandis JR et al. (2005). Mol Carcinog 42: 222–228.

  • Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI et al. (1993). Oncogene 8: 2127–2133.

  • Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE . (2005). Mol Endocrinol 19: 607–620.

  • Cam H, Dynlacht BD . (2003). Cancer Cell 3: 311–316.

  • Canhoto AJ, Chestukhin A, Litovchick L, DeCaprio JA . (2000). Oncogene 19: 5116–5122.

  • Casson AG, Zheng Z, Evans SC, Geldenhuys L, van Zanten SV, Veugelers PJ et al. (2005). Cancer 104: 730–739.

  • Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A et al. (2005). Cancer Genet Cytogenet 160: 49–54.

  • Cobrinik D . (2005). Oncogene 24: 2796–2809.

  • Coqueret O . (2002). Gene 299: 35–55.

  • Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC . (2003). Carcinogenesis 24: 1645–1650.

  • Costea I, Moghrabi A, Krajinovic M . (2003). Pharmacogenetics 13: 577–580.

  • De Wolf-Peeters C, Pittaluga S . (1994). Ann Oncol 5 (Suppl 1): 35–37.

  • Deng L, Zhao XR, Pan KF, Wang Y, Deng XY, Lu YY et al. (2002). Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 34: 16–20.

  • Dhar KK, Branigan K, Howells RE, Musgrove C, Jones PW, Strange RC et al. (1999). Int J Gynecol Cancer 9: 342–347.

  • Diehl JA . (2002). Cancer Biol Ther 1: 226–231.

  • Diehl JA, Sherr CJ . (1997). Mol Cell Biol 17: 7362–7374.

  • Diehl JA, Zindy F, Sherr CJ . (1997). Genes Dev 11: 957–972.

  • Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA . (1993). Cell 73: 499–511.

  • Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E . (2001). Ann N Y Acad Sci 952: 13–22.

  • Dufourny B, van Teeffelen HA, Hamelers IH, Sussenbach JS, Steenbergh PH . (2000). J Endocrinol 166: 329–338.

  • Ewen ME, Lamb J . (2004). Trends Mol Med 10: 158–162.

  • Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM . (1993). Cell 73: 487–497.

  • Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al. (2004). Mol Cancer Ther 3: 1427–1438.

  • Geddert H, Kiel S, Zotz RB, Zhang J, Willers R, Gabbert HE et al. (2005). J Cancer Res Clin Oncol 131: 1–6.

  • Gijtenbeek JM, Boots-Sprenger SH, Franke B, Wesseling P, Jeuken JW . (2005). J Neurooncol 74: 261–266.

  • Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C et al. (1994). Cancer Res 54: 1812–1817.

  • Gladden AB, Diehl JA . (2005). J Cell Biochem 96: 906–913.

  • Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B . (2003). Anticancer Res 23: 4257–4259.

  • Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC . (1999). Cell 98: 859–869.

  • Herber B, Truss M, Beato M, Muller R . (1994). Oncogene 9: 1295–1304.

  • Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA . (1992). Cell 70: 993–1006.

  • Holley SL, Heighway J, Hoban PR . (2005a). Int J Cancer 114: 364–370.

  • Holley SL, Matthias C, Jahnke V, Fryer AA, Strange RC, Hoban PR . (2005b). Oral Oncol 41: 156–160.

  • Holley SL, Parkes G, Matthias C, Bockmuhl U, Jahnke V, Leder K et al. (2001). Am J Pathol 159: 1917–1924.

  • Hong Y, Eu KW, Seow-Choen F, Fook-Chong S, Cheah PY . (2005). Eur J Cancer 41: 1037–1044.

  • Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A . (1997). Cancer Lett 113: 123–130.

  • Hosokawa Y, Joh T, Maeda Y, Arnold A, Seto M . (1999). Int J Cancer 81: 616–619.

  • Hosokawa Y, Tu T, Tahara H, Smith AP, Arnold A . (1995). Cancer Lett 93: 165–170.

  • Hou X, Wang S, Zhou Y, Xu Z, Zou Y, Zhu X et al. (2005). Int J Hematol 82: 206–209.

  • Howe D, Lynas C . (2001). Haematologica 86: 563–569.

  • Inoue K, Sherr CJ . (1998). Mol Cell Biol 18: 1590–1600.

  • Ito M, Habuchi T, Watanabe J, Higashi S, Nishiyama H, Wang L et al. (2004). Urology 64: 74–78.

  • Jeffrey PD, Tong L, Pavletich NP . (2000). Genes Dev 14: 3115–3125.

  • Jeon YT, Kim JW, Song JH, Park NH, Song YS, Kang SB et al. (2005). Cancer Lett 223: 259–263.

  • Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB . (1992). Cancer Res 52: 2980–2983.

  • Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH et al. (1993). Proc Natl Acad Sci USA 90: 9026–9030.

  • Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ . (1993). Genes Dev 7: 331–342.

  • Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE . (1995). J Natl Cancer Inst 87: 756–761.

  • Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN et al. (2002). N Engl J Med 347: 1566–1575.

  • Knudsen KE, Cavenee WK, Arden KC . (1999). Cancer Res 59: 2297–2301.

  • Koh J, Enders GH, Dynlacht BD, Harlow E . (1995). Nature 375: 506–510.

  • Koike H, Suzuki K, Satoh T, Ohtake N, Takei T, Nakata S et al. (2003). Anticancer Res 23: 4947–4951.

  • Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML . (2000). Cancer Res 60: 249–252.

  • Kong S, Wei Q, Amos CI, Lynch PM, Levin B, Zong J et al. (2001). J Natl Cancer Inst 93: 1106–1108.

  • Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC et al. (2003). Breast Cancer Res Treat 82: 165–168.

  • Ladha MH, Lee KY, Upton TM, Reed MF, Ewen ME . (1998). Mol Cell Biol 18: 6605–6615.

  • Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME . (2000). Mol Cell Biol 20: 8667–8675.

  • Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS et al. (2003). Cell 114: 323–334.

  • Le Marchand L, Seifried A, Lum-Jones A, Donlon T, Wilkens LR . (2003). Jama 290: 2843–2848.

  • Leng X, Noble M, Adams PD, Qin J, Harper JW . (2002). Mol Cell Biol 22: 2242–2254.

  • Lewis RC, Bostick RM, Xie D, Deng Z, Wargovich MJ, Fina MF et al. (2003). Cancer Res 63: 8549–8553.

  • Lin S, Wang W, Wilson GM, Yang X, Brewer G, Holbrook NJ et al. (2000). Mol Cell Biol 20: 7903–7913.

  • Liu E, Li X, Yan F, Zhao Q, Wu X . (2004). J Biol Chem 279: 17283–17288.

  • Liu F, Matsuura I . (2005). Cell Cycle 4: 63–66.

  • Lu F, Gladden AB, Diehl JA . (2003). Cancer Res 63: 7056–7061.

  • Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J . (1995a). Mol Cell Biol 15: 2600–2611.

  • Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen-Durr P et al. (1994a). J Cell Biol 125: 625–638.

  • Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J . (1994b). Oncogene 9: 707–718.

  • Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M et al. (1995b). Nature 375: 503–506.

  • Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF et al. (1992). Cell 71: 323–334.

  • Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY . (1994). Mol Cell Biol 14: 2066–2076.

  • Matsushime H, Roussel MF, Ashmun RA, Sherr CJ . (1991). Cell 65: 701–713.

  • Matthias C, Branigan K, Jahnke V, Leder K, Haas J, Heighway J et al. (1998). Clin Cancer Res 4: 2411–2418.

  • McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J et al. (2000). Int J Cancer 88: 77–81.

  • McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME . (1999). Proc Natl Acad Sci USA 96: 5382–5387.

  • Meyerson M, Harlow E . (1994). Mol Cell Biol 14: 2077–2086.

  • Mittnacht S . (1998). Curr Opin Genet Dev 8: 21–27.

  • Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM et al. (1991). Nature 350: 512–515.

  • Muller H, Lukas J, Schneider A, Warthoe P, Bartek J, Eilers M et al. (1994). Proc Natl Acad Sci U S A 91: 2945–2949.

  • Mumberg D, Wick M, Burger C, Haas K, Funk M, Muller R . (1997). Nucleic Acids Res 25: 2098–2105.

  • Nishimoto IN, Pinheiro NA, Rogatto SR, Carvalho AL, Simpson AJ, Caballero OL et al. (2004). Oral Oncol 40: 604–610.

  • Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ . (1994). Oncogene 9: 3375–3378.

  • Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F . (1998). Cancer Res 58: 2876–2880.

  • Pakakasama S, Chen TT, Frawley W, Muller CY, Douglass EC, Lee R et al. (2004). Oncogene 23: 4789–4792.

  • Palmero I, Peters G . (1996). Cancer Surv 27: 351–367.

  • Petre CE, Wetherill YB, Danielsen M, Knudsen KE . (2002). J Biol Chem 277: 2207–2215.

  • Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J et al. (2005). Oncogene 24: 431–444.

  • Pibiri M, Ledda-Columbano GM, Cossu C, Simbula G, Menegazzi M, Shinozuka H et al. (2001). Faseb J 15: 1006–1013.

  • Porter DC, Keyomarsi K . (2000). Nucleic Acids Res 28: E101.

  • Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S et al. (2001). Mol Cell Biol 21: 6254–6269.

  • Porter TR, Richards FM, Houlston RS, Evans DG, Jankowski JA, Macdonald F et al. (2002). Oncogene 21: 1928–1933.

  • Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S . (2003). Cancer Res 63: 958–964.

  • Qiuling S, Yuxin Z, Suhua Z, Cheng X, Shuguang L, Fengsheng H . (2003). Carcinogenesis 24: 1499–1503.

  • Ratineau C, Petry MW, Mutoh H, Leiter AB . (2002). J Biol Chem 277: 8847–8853.

  • Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z et al. (2001). Mol Endocrinol 15: 797–811.

  • Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP . (1998). Nature 395: 237–243.

  • Rydzanicz M, Golusinski P, Mielcarek-Kuchta D, Golusinski W, Szyfter K . (2005). Eur Arch Otorhinolaryngol.

  • Sabbah M, Courilleau D, Mester J, Redeuilh G . (1999). Proc Natl Acad Sci USA 96: 11217–11222.

  • Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U et al. (2004). Carcinogenesis 25: 729–734.

  • Serrano M, Hannon GJ, Beach D . (1993). Nature 366: 704–707.

  • Shapiro MB, Senapathy P . (1987). Nucleic Acids Res 15: 7155–7174.

  • Sherr CJ . (1995). Trends Biochem Sci 20: 187–190.

  • Sherr CJ, Matsushime H, Roussel MF . (1992). Ciba Found Symp 170: 209–219; discussion 219–226.

  • Sherr CJ, McCormick F . (2002). Cancer Cell 2: 103–112.

  • Shu XO, Moore DB, Cai Q, Cheng J, Wen W, Pierce L et al. (2005). Cancer Epidemiol Biomarkers Prev 14: 91–97.

  • Simpson DJ, Fryer AA, Grossman AB, Wass JA, Pfeifer M, Kros JM et al. (2001). Carcinogenesis 22: 1801–1807.

  • Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z et al. (2003). J Biol Chem 278: 30339–30347.

  • Tetsu O, McCormick F . (1999). Nature 398: 422–426.

  • Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H et al. (2005). J Med Chem 48: 2388–2406.

  • Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H et al. (2003a). Int J Cancer 103: 116–120.

  • Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y et al. (2002). Carcinogenesis 23: 257–264.

  • Wang R, Zhang JH, Li Y, Wen DG, He M, Wei LZ . (2003b). Zhonghua Yi Xue Za Zhi 83: 1089–1092.

  • Wieringa B, Meyer F, Reiser J, Weissmann C . (1983). Nature 301: 38–43.

  • Winston JT, Pledger WJ . (1993). Mol Biol Cell 4: 1133–1144.

  • Won KA, Xiong Y, Beach D, Gilman MZ . (1992). Proc Natl Acad Sci USA 89: 9910–9914.

  • Wong YK, Lin SC, Chang CS, Tseng YH, Liu CJ, Lin HC et al. (2003). J Oral Pathol Med 32: 265–270.

  • Xiong Y, Connolly T, Futcher B, Beach D . (1991). Cell 65: 691–699.

  • Yu J, Habuchi T, Tsuchiya N, Nakamura E, Kakinuma H, Horikawa Y et al. (2004). J Urol 172: 2410–2413.

  • Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU et al. (2002). Cancer Res 62: 3803–3811.

  • Zhang J, Li Y, Wang R, Wen D, Sarbia M, Kuang G et al. (2003). Int J Cancer 105: 281–284.

  • Zhang YJ, Chen SY, Chen CJ, Santella RM . (2002). Mol Carcinog 33: 125–129.

  • Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM et al. (1993). Biochem Biophys Res Commun 196: 1010–1016.

  • Zhang Z, Liu W, Jia X, Gao Y, Hemminki K, Lindholm B . (2004). Clin Chim Acta 342: 137–143.

  • Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS et al. (2001). Carcinogenesis 22: 1195–1199.

  • Zukerberg LR, Benedict WF, Arnold A, Dyson N, Harlow E, Harris NL . (1996). Blood 88: 268–276.

  • Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R . (1998). Genes Dev 12: 3488–3498.

Download references

Acknowledgements

We appreciate our colleagues in the field, and regret any omissions which may have occurred in the preparation of this review. The laboratories of Karen Knudsen and Erik Knudsen provided assistance for editorial review of the manuscript. Studies on the cyclin D1 polymorphism are supported by grants KEK: RO1-CA099996, JAD: 1R01CA111360, ESK: Comparative Mouse Genomics Centers Consortium U01-ES011038.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K E Knudsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knudsen, K., Diehl, J., Haiman, C. et al. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25, 1620–1628 (2006). https://doi.org/10.1038/sj.onc.1209371

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209371

Keywords

This article is cited by

Search

Quick links